Xencor Inc
F:XE9

Watchlist Manager
Xencor Inc Logo
Xencor Inc
F:XE9
Watchlist
Price: 10.5 EUR 2.94% Market Closed
Market Cap: 647.2m EUR

Operating Margin

-71.6%
Current
Improving
by 50%
vs 3-y average of -121.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-71.6%
=
Operating Income
$-119.8m
/
Revenue
$167.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-71.6%
=
Operating Income
€-119.8m
/
Revenue
$167.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Xencor Inc
NASDAQ:XNCR
901.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
380.6B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
182.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
158.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.5B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...
No Stocks Found

Market Distribution

Lower than 83% of companies in the United States of America
Percentile
17th
Based on 14 112 companies
17th percentile
-71.6%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Xencor Inc
Glance View

Market Cap
647.2m EUR
Industry
Biotechnology

Xencor Inc. is an innovative biotechnology company, distinguished by its commitment to harnessing the power of engineered monoclonal antibodies to fight complex diseases, especially within the realms of cancer and autoimmune disorders. Founded in 1997 and headquartered in Monrovia, California, Xencor relies on its proprietary XmAb technology platform – a sophisticated approach that enhances the structure and function of monoclonal antibodies to improve therapeutic performance. This technology enables Xencor to develop antibodies that are more potent, stable, and precise, ultimately driving their efficacy in targeting particular cellular mechanisms associated with disease progression while minimizing side effects. By focusing on core biological processes, Xencor leverages its platform to innovate new therapies that offer significant improvements over existing treatments, making it a nimble player in the competitive biotech landscape. Xencor's business model hinges on a dual strategy of internal drug development and strategic collaborations. Internally, Xencor is advancing a robust pipeline of drug candidates aimed at addressing various unmet medical needs, many of which are in various stages of clinical trials. These in-house projects are crucial for establishing the company's reputation as a leader in antibody engineering. In parallel, Xencor partners with larger pharmaceutical companies, licensing its XmAb technology and co-developing drugs—a model that provides a steady revenue stream from milestone payments, royalties, and research support. This hybrid approach not only diversifies Xencor's risk portfolio but also enhances its financial resilience, enabling a sustainable path to growth amidst the volatile biotech sector. Through this innovative framework, Xencor is poised to continue its influence in the biopharmaceutical industry, driven by a mission to bring transformative therapies to patients in need.

XE9 Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-71.6%
=
Operating Income
$-119.8m
/
Revenue
$167.4m
What is Xencor Inc's current Operating Margin?

The current Operating Margin for Xencor Inc is -71.6%, which is above its 3-year median of -121.6%.

How has Operating Margin changed over time?

Over the last 3 years, Xencor Inc’s Operating Margin has decreased from 17.5% to -71.6%. During this period, it reached a low of -255.3% on Sep 30, 2024 and a high of 17.5% on Aug 30, 2022.

Back to Top